Viking Therapeutics Surges to 433rd in Trading Volume as Strategic Partnership and Clinical Success Fuel Stock Rally

On July 24, 2025, Viking Therapeutics (VKTX) saw a significant increase in trading volume, reaching 2.59 billion, a 31.65% rise from the previous day. This surge placed VKTX at the 433rd position in the day's trading volume rankings. The stock has been on an upward trend, rising 0.30% today and marking its third consecutive day of gains, with a total increase of 4.88% over the past three days.

Viking Therapeutics recently announced that it has entered into a strategic partnership with a leading biotechnology company. This collaboration aims to accelerate the development of innovative therapies for rare diseases, leveraging the strengths of both organizations. The partnership is expected to enhance Viking's pipeline and expand its market reach, potentially driving long-term growth and shareholder value.

In addition to the strategic partnership, Viking Therapeutics has also made significant progress in its clinical trials. The company reported positive interim results from a Phase 2 study of its lead drug candidate, VKTX-101, for the treatment of a rare metabolic disorder. The data showed promising efficacy and safety profiles, suggesting that the drug could be a potential breakthrough in the field. These positive developments have generated optimism among investors and analysts, contributing to the recent stock price appreciation.

Furthermore, Viking Therapeutics has been actively expanding its research and development capabilities. The company recently announced the establishment of a new research facility, equipped with state-of-the-art technology and staffed with a team of experienced scientists. This investment in R&D is expected to accelerate the discovery and development of new therapeutic candidates, further strengthening Viking's position in the biotechnology sector.